*Result*: Unraveling mechanisms of allergen sensitization and allergic rhinitis via the nasal transcriptome.
J Allergy Clin Immunol. 2021 Aug;148(2):358-360. (PMID: 34147535)
Allergy. 2023 Nov;78(11):2959-2968. (PMID: 37615432)
J Allergy Clin Immunol. 2024 Jan;153(1):122-131. (PMID: 37742934)
Ann Allergy Asthma Immunol. 2022 Apr;128(4):414-422.e2. (PMID: 35031416)
Nat Rev Dis Primers. 2020 Dec 3;6(1):95. (PMID: 33273461)
Allergy. 2022 Jun;77(6):1772-1785. (PMID: 34839541)
Eur Respir J. 2012 May;39(5):1197-205. (PMID: 22005912)
Mucosal Immunol. 2017 Mar;10(2):408-420. (PMID: 27677865)
Allergy. 2020 Mar;75(3):695-698. (PMID: 31541610)
J Leukoc Biol. 2015 Aug;98(2):185-94. (PMID: 26026068)
J Allergy Clin Immunol. 2022 Nov;150(5):1232-1236. (PMID: 35718139)
J Allergy Clin Immunol. 2021 Mar;147(3):879-893. (PMID: 32828590)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Allergy. 2024 Apr;79(4):894-907. (PMID: 38279910)
J Allergy Clin Immunol. 2021 Feb;147(2):694-703.e12. (PMID: 32717253)
Nat Rev Immunol. 2015 May;15(5):271-82. (PMID: 25882242)
PLoS One. 2014 May 01;9(5):e94776. (PMID: 24787549)
Ann Allergy Asthma Immunol. 2024 Aug;133(2):177-185.e10. (PMID: 38679157)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cell. 2021 Mar 18;184(6):1469-1485. (PMID: 33711259)
Cytokine. 2015 Sep;75(1):68-78. (PMID: 26070934)
Allergy. 2008 Apr;63 Suppl 86:8-160. (PMID: 18331513)
Nat Genet. 2000 May;25(1):25-9. (PMID: 10802651)
Genome Med. 2023 Sep 20;15(1):71. (PMID: 37730635)
J Allergy Clin Immunol. 2023 May;151(5):1191-1203.e3. (PMID: 36958985)
Nat Genet. 2008 Jul;40(7):854-61. (PMID: 18552845)
J Allergy Clin Immunol. 2017 Oct;140(4):909-920. (PMID: 28987220)
Adipocyte. 2012 Apr 1;1(2):96-100. (PMID: 23700518)
Pediatr Allergy Immunol. 2021 Nov;32(8):1691-1699. (PMID: 34310772)
J Clin Immunol. 2010 Nov;30(6):830-9. (PMID: 20683648)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Allergy. 2020 Dec;75(12):3248-3260. (PMID: 32277847)
*Further Information*
*Background: Allergen sensitization is a critical early step in the pathogenesis of allergic disease. Different allergens likely trigger distinct immune pathways in the nasal epithelium.
Objective: Our aim was to examine molecular mechanisms in the nasal epithelium for sensitization to different allergens.
Methods: We recruited 301 participants and profiled their sensitization to 10 allergens and nasal epithelial transcriptome. Differential expression, gene ontology, causal network, and key driver analyses were performed to identify molecular processes underlying sensitization to indoor allergens, pollens, and pet allergens, as well as for allergic rhinitis (AR).
Results: The cohort was 48.8% female, with a mean age of 13.2 years (SD = 4.1 years). Most of the cohort was sensitized to at least 1 allergen, with 74.1% sensitized to an indoor allergen, 60.1% pollen sensitized, and 68.1% pet sensitized. In all, 51.8% of the cohort had AR. Using a discovery and test set framework for rigor, we identified and validated 185 transcripts associated with allergen sensitization. Probabilistic causal network and key driver analyses identified a network for allergen sensitization spanning 4 subnetworks for lymphocyte chemotaxis, mast cell, IL-4, and antiviral response. Although the key drivers and transcripts for indoor allergen sensitization mapped to the lymphocyte chemotaxis and antiviral response subnetworks, those for pollen sensitization mapped to the mast cell and IL-4 subnetworks. Pet sensitization mapped to lymphocyte chemotaxis, mast cell, and IL-4. The key drivers for AR significantly overlapped with those for allergen sensitization.
Conclusion: Causal network analysis of nasal transcriptome revealed allergen-specific biologic processes and key drivers underlying sensitization and AR.
(Copyright © 2025 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)*
*Disclosure statement Supported by the National Institutes of Health (grant R01 AI118833 to S.B.). Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.*